OVO Biomanufacturing, a spin-out from the University of Warwick and Coventry University, is developing a platform to improve the efficacy of vaccine and gene therapy manufacture.
Why we like the business
OVO Biomanufacturing’s technology allows manufacturers of viral vaccines and gene therapies to maximise the production of the target virus used to produce a vaccine or therapy. Improving the efficacy of manufacture can improve yield, cut lead times and costs and maximise distribution. The resulting increase in availability and affordability of vaccines worldwide is key in the fight against the current and future pandemics.